What is the primary purpose of the new Term Loan Agreement?

The primary purpose of the $5.0 billion Term Loan Agreement is to provide financing for CVS Health's proposed merger with Aetna Inc. It replaces a portion of a previously committed bridge facility.

What are the key terms of the new Term Loan Agreement?

The Term Loan Agreement provides for $5.0 billion in unsecured term loans, split into a $3.0 billion three-year tranche and a $2.0 billion five-year tranche. The interest rates are based on either the Eurodollar rate or base rate plus an applicable margin determined by credit ratings. The five-year tranche has scheduled amortization.

How do the amendments to the revolving credit agreements affect CVS Health's financial flexibility regarding the Aetna merger?

The amendments allow CVS Health to incur additional subsidiary debt up to a certain limit (initially excluding Aetna's existing debt), expressly permit the Aetna merger under acquisition covenants, and temporarily adjust the consolidated indebtedness to total capitalization ratio to a higher level (0.65:1.00) and exclude up to $49.0 billion in merger financing from this calculation. These changes provide necessary flexibility for the transaction.

Are there any significant financial covenants or restrictions related to these new financing arrangements?

Yes, the Term Loan Agreement and amended revolving credit agreements include several covenants. These include limitations on liens, dispositions, mergers, acquisitions, and restricted payments. A key financial covenant is the consolidated indebtedness to total capitalization ratio, which has specific limits and exceptions related to the Aetna merger financing.

CVS 8-K: Material Agreements & Financial Events

Summary

This Current Report on Form 8-K filed by CVS Health Corporation on December 19, 2017, primarily details significant financing arrangements related to its previously announced merger with Aetna Inc. The company entered into a $5.0 billion Term Loan Agreement, which reduces a prior bridge facility commitment. This new facility is comprised of a $3.0 billion three-year tranche and a $2.0 billion five-year tranche, both of which are unsecured. Additionally, CVS Health executed amendments to its existing revolving credit facilities. These amendments include adjustments to covenants regarding subsidiary debt incurrence, expressly permit the Aetna merger, and modify financial covenants related to the debt-to-capitalization ratio. These financing actions are crucial steps in securing the necessary capital and maintaining financial flexibility for the proposed acquisition of Aetna.

Key Highlights

1CVS Health entered into a $5.0 billion unsecured Term Loan Agreement on December 15, 2017, as part of its proposed merger with Aetna.
2The Term Loan Agreement consists of a $3.0 billion three-year tranche and a $2.0 billion five-year tranche.
3This new $5.0 billion term loan replaces a portion of a previously announced $49.0 billion bridge facility.
4Amendments were made to existing revolving credit agreements to accommodate the Aetna merger, including adjustments to debt covenants and financial ratios.
5Key covenants in the Term Loan Agreement include limitations on liens, dispositions, mergers, acquisitions, restricted payments, and a consolidated indebtedness to total capitalization ratio limit.
6The amendments to revolving credit facilities relax certain debt incurrence restrictions for subsidiaries and permit the Aetna merger, while also temporarily adjusting the consolidated indebtedness to total capitalization ratio.
7The effective date for the Term Loan Agreement conditions was met on December 15, 2017.

CVS HEALTH Corp 8-K Report, Material Agreement (Dec 19, 2017)

Summary

Key Highlights

Frequently Asked Questions